Myelomatosis

Fundamentals and Clinical Features

I. Snapper and A. Kahn

With 90 figures and 24 tables


Originally published by S. Karger AG, Basel, Switzerland
Distributed exclusively in the United States of America and Canada by University
Park Press, Baltimore, Maryland
Library of Congress Catalog Card Number 71-150241

Authors’ addresses:

I. Snapper, M.D., Consultant-in-Residence and Chief of the Bence Jones Protein
Laboratory Veterans Administration Hospital, Brooklyn, N.Y.
A. Kahn, M.D., Director of Medical Education, Brookdale Hospital Center,
Brooklyn, N.Y.

S. Karger Basel München Paris London New York Sydney
Arnold-Bcklin-Strasse 25, CH-4000 Basel 11 (Switzerland)
All rights, including that of translation into other languages, reserved.
Photomechanic reproduction (photocopy, microcopy) of this book or part thereof
without special permission of the publishers is prohibited.
Copyright 1971 by S. Karger AG, Verlag fr Medizin und Naturwissenschaften, Basel
Printed in Switzerland by Tanner & Bosshardt AG, Basel

Table of Contents

Foreword................................................................ XI
Acknowledgments......................................................... XIII
Introduction.................................................................... XV
1. Historical Background
Nineteenth Century ...................................................... 1
Twentieth Century........................................................ 8
2. Myeloma Cells
Histologic features........................................................ 10
Cytoplasmic vacuoles..................................................... 15
Bence Jones proteinuria in essential monoclonal M-globulinemia................. 78
Anatomical differences between myelomatous and nonmyelomatous monoclonal immunoglobulinemia.................................................. 79
Bone marrow findings.......................................................... 80
Differences between nonmyelomatous monoclonal IgG and normal IgG........ 81
6. Aleutian Mink Disease................................................ 84
7. Polyclonal Hyperglobulinemia............................................. 86
8. Bence Jones Protein
Fundamentals
Chemical and physicochemical features ....................................... 89
Heterogeneity of Bence Jones protein........................................ 90
Production of Bence Jones protein............................................ 97
Metabolism........................................................................ 99
9. Experimental Myelomatosis ........................................... 101
10. Ancillary Laboratory Methods
Calcium and phosphorus .................................................. 106
Alkaline and acid phosphatase............................................ 110
Uric acid........................................................................ 110
Magnesium.................................................................... 111
Hyperproteinemia and hyperglobulinemia .................................. 111
11. Age Distribution and Geographic Spread.............................. 113

Table of Contents VII
12. Natural History of the Disease
General remarks.................................................................. 117
Connections between Bence Jones proteinuria and prognosis............ 119
Histories of four myelomatosis patients admitted between 1956 and 1958 who survived for five years or more................................. 120
13. Familial Occurrence and Chromosomal Abnormalities
Familial cases .................................................................... 130
Chromosomal abnormalities ............................................. 131
Changes in karyotype .......................................................... 131
Acquired postnatal mutation............................................... 133
Genetic predisposition of gammapathies............................... 136
14. Hematologic Signs
Anemia........................................................................... 138
Leukocytes and plasma cell leukemia .................................... 141
Thrombocytopenia and other forms of hemorrhagic tendency ............ 146
Sedimentation rate of erythrocytes........................................ 147
15. Generalized Bone Disease
Pains ............................................................................ 149
Pathologic fractures.......................................................... 151
Hyperviscosity syndrome .......................................................... 228
Cryoglobulinemia and hypercalcemia ........................................ 229
21. Raynaud's Syndrome, Cryo-Insoluble IgG and IgM, Mixed Cryoglobulins, Cold Agglutinins, Pyroglobulins
Cryoglobulins ........................................................................ 232
Introduction ........................................................................... 232
Cryo-insoluble IgG or IgM ...................................................... 232
Mixed cryoglobulins ............................................................. 233
Cold agglutinins ..................................................................... 235
Pyroglobulins ......................................................................... 236
22. Amyloidosis: Familial, Primary, Myelomatous and Secondary Forms
Chemical and physicochemical features ..................................... 238
Histochemical diagnosis of amyloid ........................................ 239
Different forms of amyloid ..................................................... 240
Introduction ........................................................................... 240
Familial amyloidosis ............................................................ 241
Primary amyloidosis and paramyloidosis in myelomatosis .......... 241
Pathogenesis of primary and myelomatous paramyloidosis ....... 244
Secondary amyloidosis .......................................................... 245
Localization ........................................................................... 245
Pathogenesis of secondary amyloidosis .................................... 246
Histologic differences ......................................................... 250
Diagnosis ............................................................................... 251
Clinical features of paramyloidosis in myelomatosis and primary amyloidosis .... 252
Introduction ........................................................................... 252
Kidney ..................................................................................... 253

Table of Contents IX

Musculature ............................................................................ 255
Synovia .................................................................................... 257
Subcutis, lymph nodes............................................................ 259
Intestine .................................................................................... 260
Other systems .......................................................................... 261
23. Autopsy Findings in Myelomatosis
Myocardial infarction ............................................................ 263
Bronchogenic and other carcinomas ........................................ 264
Bronchopneumonia and pyelonephritis .................................. 266
Myeloma kidney and nephrocalcinosis ..................................... 266
24. Solitary and Multiple Intraosseous Plasmacytomas ............... 267
25. Extramedullary Plasmacytomas
In patients with generalized myelomatosis ............................. 271
Primary extramedullary plasmacytomas.............................................. 272
26. Macroglobulinemia, Waldenstrom's Disease
   Introduction............................................................. 276
   Clinical features........................................................ 277
   Macroglobulins .......................................................... 280
   The Sia test.............................................................. 280
   Connection of Waldenstrom's disease with myelomatosis and lymphoma....... 284
   Familial features and chromosomal changes.................................. 285
   Secondary macroglobulinemia.............................................. 286
27. Franklin's Disease and Alpha Chain Disease
   Fc fragment ............................................................. 288
   Heavy alpha chain disease............................................. 290
   Heavy M (Mu) chain disease........................................... 291
28. Treatment of Myelomatosis and other Gammapathies
   Introduction............................................................. 293
   Modern alkylating agents................................................ 293
   Guidelines for the determination of the influence of alkylating agents upon the
   course of myelomatosis. The scoring system of Carbone et al................. 294
   Melphalan (Alkeran)...................................................... 296
   Three recent surveys.................................................. 296
   Results.......................................................................... 299
   Connection between antigenic type of light chains and response to melphalan
   treatment................................................................. 300
   Survival rates.................................................................. 301
   Administration of melphalan combined with prednisone................... 302
   Our own experience...................................................... 304
   Conclusions.............................................................. 306
   Cyclophosphamide........................................................ 307

Table of Contents X

Treatment of the hypercalcmie syndrome........................................... 309
Treatment of the hyperviscosity syndrome.................................... 310
Treatment with sodium fluoride.................................................. 311
X-ray treatment................................................................. 314
ACTH and cortisone therapy ................................................... 315
Older methods of treatment...................................................... 315
Urethane............................................................................. 315
Stilbamidine derivatives ........................................................ 317
Treatment of Waldenstrom's disease............................................ 318
Treatment of amyloidosis....................................................... 319
References........................................................................ 320
Foreword

In the era of so-called 'modern medicine', there has possibly been no disease which has been the subject of greater interest and more fruitful investigation than multiple myeloma, and no single investigator who has contributed more to this subject than Dr. Snapper. Seventeen years have now elapsed since publication of the now-classic treatise Multiple Myeloma by I. Snapper, L.B. Turner and H.L. Moscovitz (Grune and Stratton, New York, 1953). This work represented a thoroughly scholarly review of the then-available clinical and biochemical information on myeloma and an equally comprehensive analysis of Dr. Snapper's personal series of 97 cases.

To this day there is no better description of the diverse and complex manifestations of the disease, exquisitely analyzed by one of the world's truly superb physician-investigators. Thus, what to many at the time was still regarded as a rare and usually dismal bone cancer, was recognized by Dr. Snapper to be a particularly challenging 'metabolic' disease with broad implications in the areas of pathophysiology, biochemistry and immunology. Clearly, the impressive wealth of information which has been added in the intervening 17 years to our knowledge of myeloma proteins as well as clinical myeloma and related diseases has amply affirmed Dr. Snapper's original convictions.

As detailed in this present volume, extensive studies of myeloma proteins have provided much of our present understanding of the composition and structure of normal immunoglobulins. Indeed, there is increasing evidence that certain myeloma proteins may in fact be functional antibodies produced in great excess as a consequence of the excessive proliferation of plasma cells.

With regard to the clinical aspects of myeloma, the past several years have also witnessed impressive progress, not only with respect to improved diagnostic methods but also more effective chemotherapy and increased survival.

Foreword XII

Thus, it is greatly welcomed to have the subject of myeloma and myeloma proteins surveyed and re-appraised by a physician and clinical-investigator non-pareil, Dr. I. Snapper.

December, 1970
Elliott F. Osserman, M.D.
American Cancer Society Research
Professor of Pathology Columbia
University College of Physicians and
Surgeons

Acknowledgments

We are deeply grateful to many persons for their generous and gracious interest and assistance in the preparation of this monograph:
Drs. Elliott Osserman, David Spain, Irwin Bluth, Joshua Derow, Charles Newman, Henry Azar, Richard Ores, and Esmond Davison provided data, roentgenographs and photographs, many of which have been acknowledged in their respective captions.
Drs. Hyman Katz, Robert Axelrod, and J. Muntinghe read several chapters and their constructive criticism led to revision and reorganization of the manuscript. Dr. William Dock gave us the benefit of his judgment on some of the chapters covering clinical problems of myelomatosis.
Dr. Fidelio Jimenez put his wide experience at our disposal by actively participating in the preparation of histologic sections of material obtained by bone marrow puncture.
Dr. Leo Vroman made the original line drawings which illustrate the intricate aspects of the recent advances in immunochemistry.
Mr. Jim Snapper prepared the karyotype.
The staff of the Department of Medical Illustration of the Brooklyn Veterans Administration Hospital prepared outstanding reproductions and photographs.
The logetronic reproductions of the roentgenograms made by Mr. Robert Carlin were as always superior in quality.
The Royal Academy of Medicine in London sent two photographs of Henry Bence Jones, one of which has been chosen as the frontispiece.
The librarians of the New York Academy of Medicine, Brooklyn Veterans Administration Hospital and Jacobi Library of the Mount Sinai Hospital were at all times ready to cooperate by locating and making available reference material in many different languages.
Dr. Ezra Greenspan, in the name of the Chemotherapy Foundation of New York, presented a liberal gift which helped to defray costs incurred in the preparation of the manuscript.
The able staff members of the Bence Jones protein laboratory of the Brooklyn Veterans Administration Hospital - Mrs. Barbara Iverson, Dr. David Seld, Dr. Louis Stevens, and Dr. Victor Sousa - were a continuous inspiration during the years spent in the completion of this book.

Henry Bence Jones

Introduction
The complicated disease nowadays known as multiple myeloma or myelomatosis first came to the attention of the medical profession when MacIntyre and Bence Jones in 1845 discovered a unique protein in the urine of a patient suffering from an unknown ailment. Before the pathogenesis of the disease was well understood, it was necessary for several generations of investigators to formulate and test an impressive variety of theories. The diagnosis made at the autopsy of the first patient in 1846 was mollities ossium, ‘softening of the bones’. For the next four decades the few physicians interested in this syndrome were unable to differentiate the new disease from osteomalacia. In 1885, however, Kahler correctly concluded that the presence of the unusual protein in the urine excluded the possibility of osteomalacia and strongly militated in favor of a myeloma, the pathology of which had in the meantime been described by Rustizky.

Physicians working on the problems of myelomatosis were for a long time interested mainly in the skeletal changes, visualized on roentgenograms. Soon it became evident that roentgenologically this disease was characterized by a generalized ‘decalcification’ of the skeleton complicated by the presence of round, sharply defined, punched out osteolytic areas. At the same time no manifestations of new formation of bone could be found. Interesting as these bone lesions are, there can be no doubt that in a significant number of myelomatosis patients no clear-cut roentgenologic skeletal changes can be demonstrated.

As long as the histologic analysis of the skeleton of these patients was limited to the study of bone biopsies, only the profuse proliferation of abnormal bone marrow elements could be observed. The ancestry of the proliferating cells had yet to be traced. When in 1929 bone marrow punctures were introduced in the practice of medicine, the proliferation of immature, probably malignant plasma cells in the diseased bone marrow became the all-important feature of the disease. Anemia being one of the most common manifestations of myeloma, the hematologists’ practice of performing bone marrow punctures in every anemic patient permits many utterly unsuspected cases of myelomatosis to be recognized by serendipity, hereby greatly increasing the number of cases of myeloma diagnosed during life.

In the course of the years interest of many physicians had turned to other clinical aspects of the disease. The published reports on the subject of myeloma dealt with such aspects as:

(1) anemia, thrombocytopenia, coagulation disorders, and other hematologic dyscrasias;
(2) connection between myeloma
and plasma cell leukemia;
(3) very high sedimentation of the red cells;
(4) uremia - usually due to renal damage caused by Bence Jones proteinuria;
(5) hypercalcemia and hypercalciuria - in the absence of an increased
alkaline phosphatase of the serum;
(6) Raynaud's syndrome - usually due to cryoglobulinemia;
(7) decreased resistance against tuberculosis, fungus diseases and other
infections, - pneumonia and pyelonephritis being the most frequent manifestations
of bacterial invasions;
(8) paramyloidosis - mainly localized in musculature and mesenchymatous
tissues;
(9) neurological complications - often due to hyperviscosity of serum
and hypercalcemia;
(10) relationship between generalized myelomatosis and solitary intraosseous
or extramedullary plasmacytomas;
(11) connections between myelomatosis and Waldenstrom's macroglobulinemia;
(12) different modalities of heavy chain disease.
Notwithstanding the many different serious manifestations of myelomatosis,
many patients suffering from this disease are walking around considering
themselves to be completely healthy individuals. Patients may have
none of the symptoms or signs of myelomatosis although their entire bone
marrow is replaced by rapidly growing myeloma cells.
It soon became evident that the changes of the protein metabolism
characteristic for myelomatosis are of paramount importance for the pathogenesis,
diagnosis and prognosis of the disease. Researchers were obliged
to become experts in immunochemistry, in order to be able to grasp the
significance of many of the intricacies of the myelomatous proteins. Better
understanding of these complicated problems has in turn clarified many of
the chameleonic symptoms and signs of this disease.
For myelomatosis there is still no cure, but a faint ray of hope may now
be visible on the horizon.
The circle has closed. In the first myelomatosis patient the disease of the
skeleton was not recognized during life but a hitherto unknown protein had
been discovered in the urine. We have now returned to the study of the abnormal
myeloma proteins though with more sophisticated techniques.
In our choice of a sequence of chapters for this monograph we have been
guided by the triad of examinations essential for the diagnosis, prognosis,
and treatment of myelomatosis, i.e. bone marrow puncture, serum electrophoresis,
and search for Bence Jones protein. Therefore, after a short historical
review, the multifaceted subject of myelomatosis is approached by preliminary chapters on: histology of bone marrow; immunoglobulins; and investigation of structure and metabolism of Bence Jones protein. Since certain other fundamental problems and laboratory methods could not be ignored, the discussion of clinical aspects of the disease was tackled last.